Mizuho Downgrades Adaptimmune Therapeutics (NASDAQ:ADAP) to Neutral

Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by investment analysts at Mizuho from an “outperform” rating to a “neutral” rating in a report issued on Thursday, MarketBeat Ratings reports. They presently have a $0.50 price objective on the biotechnology company’s stock, down from their previous price objective of $1.50. Mizuho’s target price would suggest a potential upside of 104.08% from the stock’s current price.

A number of other analysts have also commented on ADAP. Barclays reduced their target price on Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating for the company in a report on Wednesday, May 14th. Wall Street Zen began coverage on Adaptimmune Therapeutics in a report on Friday, May 16th. They issued a “buy” rating for the company. Guggenheim reduced their price objective on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a report on Wednesday, March 26th. Wells Fargo & Company reduced their price objective on Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating for the company in a report on Wednesday, May 14th. Finally, Jones Trading lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Adaptimmune Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $1.35.

Adaptimmune Therapeutics Stock Up 1.2%

NASDAQ:ADAP opened at $0.25 on Thursday. The firm has a market cap of $64.94 million, a P/E ratio of -0.91 and a beta of 2.24. The company has a debt-to-equity ratio of 4.24, a quick ratio of 1.79 and a current ratio of 2.02. Adaptimmune Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.48. The firm has a 50-day simple moving average of $0.27 and a two-hundred day simple moving average of $0.41.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18). The company had revenue of $7.29 million during the quarter, compared to the consensus estimate of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative return on equity of 163.73%. Analysts predict that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Adaptimmune Therapeutics

Several large investors have recently modified their holdings of ADAP. Acadian Asset Management LLC grew its stake in shares of Adaptimmune Therapeutics by 334.8% during the 1st quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company’s stock valued at $424,000 after purchasing an additional 1,707,999 shares during the period. Two Seas Capital LP grew its position in Adaptimmune Therapeutics by 38.4% during the first quarter. Two Seas Capital LP now owns 20,529,685 shares of the biotechnology company’s stock valued at $4,044,000 after buying an additional 5,694,539 shares during the period. Long Focus Capital Management LLC grew its position in Adaptimmune Therapeutics by 15.9% during the first quarter. Long Focus Capital Management LLC now owns 23,756,687 shares of the biotechnology company’s stock valued at $4,680,000 after buying an additional 3,262,294 shares during the period. Two Sigma Investments LP grew its position in Adaptimmune Therapeutics by 33.5% during the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 19,146 shares during the period. Finally, Two Sigma Advisers LP grew its position in Adaptimmune Therapeutics by 492.0% during the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares during the period. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.